Welcome to our dedicated page for Mural Oncology plc Ordinary Shares news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology plc Ordinary Shares stock.
Mural Oncology plc (Nasdaq: MURA) is a clinical-stage immuno-oncology company focused on the discovery and development of innovative immunotherapies to significantly improve the lives of cancer patients. The company specializes in immune cell modulation and protein engineering to create novel cytokine therapies that address areas of unmet need.
Mural's leading product candidate, nemvaleukin alfa (nemvaleukin), is an engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while reducing toxicities. Nemvaleukin is currently in two potentially registrational trials: one for mucosal melanoma and another for platinum-resistant ovarian cancer (PROC), both with results expected in 1Q 2025. Additionally, nemvaleukin is being evaluated in a less frequent dosing regimen in cutaneous melanoma.
Beyond nemvaleukin, Mural Oncology is advancing discovery-stage programs targeting interleukin-18 (IL-18) and interleukin-12 (IL-12), with plans to nominate development candidates for each in 2024. These programs leverage Mural's expertise in cytokine biology and protein engineering to create therapies that could potentially overcome the limitations of existing immunotherapies.
Formed as a spin-out from Alkermes plc in November 2023, Mural Oncology started with $275 million in committed funding, providing financial stability projected into 4Q 2025. The company is led by a team of seasoned oncology experts and utilizes its innovative approaches to protein engineering to push the boundaries of cancer treatment.
For more information, visit Mural Oncology’s website at www.muraloncology.com and follow them on LinkedIn and X.
Mural Oncology (Nasdaq: MURA) announced Q1 2024 financial results and a business update. Key highlights include ongoing clinical trials for nemvaleukin alfa in ovarian cancer and melanoma, with readouts expected in 1H 2025. Mural is also evaluating a new, less frequent IV dose of nemvaleukin. Preclinical data on IL-18 and IL-12 therapies were presented in April 2024, with candidate nominations anticipated by year-end.
Financially, Mural reported a net loss of $30.9 million, improved from $46.5 million YoY. Cash reserves stand at $231.7 million, expected to fund operations into Q4 2025. R&D expenses decreased to $26.9 million, while G&A expenses rose to $7.2 million, reflecting standalone public company costs.
Mural Oncology plc announced the granting of non-statutory stock options and restricted stock units to three newly hired employees as inducement material. The stock options have an exercise price of $3.78 per share, with a ten-year term and vesting over four years. The restricted stock units also vest over four years, 25% per year, subject to continued service with the Company.
FAQ
What is the current stock price of Mural Oncology plc Ordinary Shares (MURA)?
What is the market cap of Mural Oncology plc Ordinary Shares (MURA)?
What is Mural Oncology's primary business focus?
What is nemvaleukin alfa?
What are the current clinical trials for nemvaleukin?
What other programs is Mural Oncology developing?
Where is Mural Oncology headquartered?
How was Mural Oncology formed?
Who is leading Mural Oncology?
What financial runway does Mural Oncology have?
What sets Mural Oncology apart in the field of immuno-oncology?
How can I get more information about Mural Oncology?
